Coherus BioSciences, Inc.
CHRS
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PDā¦ read more
Healthcare
Biotechnology
11 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.34
Price-10.07%
-$0.15
1Y
Price
Market Cap
$155.745m
Small
Price/Earnings 3y Avg5y Avg
2.4x
Premium
Premium
Financials Overview
Key metrics over the past few years-443.6%
EBITDA Margin+2903.9%
Net Profit Margin-454.8%
Free Cash Flow MarginRevenue
$142.771m
-46.5%
1y CAGR-7.0%
3y CAGR-14.1%
5y CAGREarnings
$179.751m
+530.6%
1y CAGR+220.3%
3y CAGR+164.8%
5y CAGREPS
-$1.38
-652.0%
1y CAGR-169.8%
3y CAGR-127.0%
5y CAGRBook Value
$119.827m
$439.464m
Assets$319.637m
Liabilities$2.406m
DebtDebt to Assets
0.6%
-
Debt to EBITDAFree Cash Flow
-$105.866m
-417.9%
1y CAGR-100.6%
3y CAGR-207.4%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company